DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of EUR 29.68 billion. The enterprise value is 29.57 billion.
Market Cap | 29.68B |
Enterprise Value | 29.57B |
Important Dates
The last earnings date was Thursday, May 1, 2025.
Earnings Date | May 1, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | -3.45% |
Shares Change (QoQ) | +0.20% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 389.26M |
Valuation Ratios
The trailing PE ratio is 59.94.
PE Ratio | 59.94 |
Forward PE | n/a |
PS Ratio | 7.73 |
PB Ratio | 14.15 |
P/TBV Ratio | 14.93 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 37.32, with an EV/FCF ratio of 55.57.
EV / Earnings | 59.72 |
EV / Sales | 8.04 |
EV / EBITDA | 37.32 |
EV / EBIT | 52.71 |
EV / FCF | 55.57 |
Financial Position
The company has a current ratio of 1.50, with a Debt / Equity ratio of 1.14.
Current Ratio | 1.50 |
Quick Ratio | 1.27 |
Debt / Equity | 1.14 |
Debt / EBITDA | 2.89 |
Debt / FCF | 4.49 |
Interest Coverage | 33.12 |
Financial Efficiency
Return on equity (ROE) is 23.72% and return on invested capital (ROIC) is 8.16%.
Return on Equity (ROE) | 23.72% |
Return on Assets (ROA) | 5.98% |
Return on Invested Capital (ROIC) | 8.16% |
Return on Capital Employed (ROCE) | 17.03% |
Revenue Per Employee | 374,413 |
Profits Per Employee | 48,309 |
Employee Count | 10,300 |
Asset Turnover | 0.63 |
Inventory Turnover | 2.90 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.75% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -36.75% |
50-Day Moving Average | 66.53 |
200-Day Moving Average | 70.06 |
Relative Strength Index (RSI) | 67.88 |
Average Volume (20 Days) | 90 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 2.29 |
Income Statement
In the last 12 months, DexCom had revenue of EUR 3.84 billion and earned 495.17 million in profits. Earnings per share was 1.23.
Revenue | 3.84B |
Gross Profit | 2.28B |
Operating Income | 585.28M |
Pretax Income | 676.14M |
Net Income | 495.17M |
EBITDA | 793.64M |
EBIT | 585.28M |
Earnings Per Share (EPS) | 1.23 |
Balance Sheet
The company has 2.50 billion in cash and 2.39 billion in debt, giving a net cash position of 109.36 million.
Cash & Cash Equivalents | 2.50B |
Total Debt | 2.39B |
Net Cash | 109.36M |
Net Cash Per Share | n/a |
Equity (Book Value) | 2.10B |
Book Value Per Share | 5.35 |
Working Capital | 1.40B |
Cash Flow
In the last 12 months, operating cash flow was 891.99 million and capital expenditures -359.81 million, giving a free cash flow of 532.18 million.
Operating Cash Flow | 891.99M |
Capital Expenditures | -359.81M |
Free Cash Flow | 532.18M |
FCF Per Share | n/a |
Margins
Gross margin is 59.43%, with operating and profit margins of 15.25% and 12.90%.
Gross Margin | 59.43% |
Operating Margin | 15.25% |
Pretax Margin | 17.62% |
Profit Margin | 12.90% |
EBITDA Margin | 20.68% |
EBIT Margin | 15.25% |
FCF Margin | 13.87% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 3.45% |
Shareholder Yield | 3.45% |
Earnings Yield | 1.67% |
FCF Yield | 1.79% |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4.
Last Split Date | Jun 13, 2022 |
Split Type | Forward |
Split Ratio | 4 |
Scores
DexCom has an Altman Z-Score of 6.35.
Altman Z-Score | 6.35 |
Piotroski F-Score | n/a |